Arizona

Start Pallas's online intake — it takes about 5 minutes and covers your health history, goals, and current medications. A provider authorized to treat Arizona patients reviews it, and because Arizona allows asynchronous-first care for non-controlled medications like GLP-1s, that review can happen by secure message without a scheduled video call, unless your history calls for one. If a GLP-1 is clinically appropriate, your clinician prescribes it, and a US-licensed pharmacy ships your medication to any Arizona address in 2–3 business days.

The process is the same as for semaglutide — complete Pallas's online intake, and a provider authorized to treat Arizona patients reviews it, asynchronously in most cases, since Arizona allows telehealth providers to establish care and prescribe without a live video visit when the standard of care is met. If appropriate, your clinician can prescribe compounded tirzepatide, prepared per-patient by a US-licensed §503A compounding pharmacy based on a documented clinical rationale, or an FDA-approved brand-name option like Zepbound^® or Mounjaro^®, through the same intake. These are distinct products with different regulatory status; your clinician will explain which fits you.

Yes — compounded semaglutide is available to eligible Arizona residents through licensed telehealth. It is prepared per-patient by US-licensed 503A and 503B compounding pharmacies under FDCA §503A, and a provider authorized to treat Arizona patients must prescribe it based on a documented, patient-specific clinical rationale. Pallas works only with U.S. state-licensed 503A and 503B compounding pharmacies and serves Arizona with free shipping. FDA-approved brand-name options like Wegovy^® and Zepbound^® are also available through the same intake.

Yes. Arizona is a full-practice-authority state — the Arizona Board of Nursing grants Arizona nurse practitioners independent prescribing and dispensing authority, with no physician supervision or collaborative agreement required (A.R.S. §32-1601(23); A.A.C. R4-19-511). Semaglutide and tirzepatide are not controlled substances, so Arizona also allows the provider-patient relationship to be established entirely through telehealth. Every Pallas clinician who treats Arizona patients holds an active Arizona license or is registered to practice telehealth in Arizona under HB 2454.

Several licensed telehealth platforms serve Arizona residents seeking compounded semaglutide. Before choosing one, verify that its clinicians are licensed or registered to practice telehealth in Arizona, that it works with US-licensed §503A compounding pharmacies, and that it holds LegitScript Healthcare Merchant Certification — you can check any platform's certification status in LegitScript's public database. Pallas serves Arizona residents and is LegitScript Healthcare Merchant Certified.

AHCCCS covers GLP-1s like semaglutide for type 2 diabetes with prior authorization. Coverage for weight-management indications is limited. Compounded GLP-1s are not covered. Pallas is a cash-pay service, so AHCCCS coverage does not apply to our prescriptions.

Sometimes. Under Arizona HB 2454, qualifying out-of-state providers may register with the Arizona Medical Board to treat Arizona patients via telehealth. All Pallas clinicians who treat Arizona patients either hold an active Arizona license or are registered to practice telehealth under this pathway.

No — Arizona allows asynchronous-first care. A provider authorized to treat Arizona patients can review your intake by secure message and, if appropriate, prescribe semaglutide without a scheduled video call, provided the standard of care is met. Your provider may request a brief video visit or additional information only if your history calls for it.

Most Arizona patients receive their medication within 2–3 business days of the pharmacy filling the prescription. Phoenix, Tucson, Mesa, and Scottsdale typically ship fastest; remote desert, mountain, and reservation ZIP codes may take an extra day.

Eligibility is always decided by a clinician authorized to treat Arizona patients after reviewing your full intake, never by an automated quiz. In general, GLP-1 medications for weight management are considered for adults with a BMI of 30 or higher, or a BMI of 27 or higher together with a weight-related condition such as high blood pressure, type 2 diabetes, high cholesterol, or obstructive sleep apnea. Your clinician also reviews your medical history and current medications to confirm a GLP-1 is appropriate and safe for you, and will tell you if it is not.

Brand-name medications — Wegovy^® and Ozempic^® (semaglutide) and Zepbound^® and Mounjaro^® (tirzepatide) — are FDA-approved products from their manufacturers, offered cash-pay. Compounded semaglutide and tirzepatide are prepared on a per-patient basis by US-licensed compounding pharmacies, regulated under federal law (FDCA §503A) and by state boards of pharmacy, when a clinician documents a patient-specific clinical need. While these pharmacies are highly regulated, the compounded medications themselves are not FDA-approved, are not generic versions of brand-name drugs, and have not been evaluated by the FDA for safety, efficacy, or quality. Which option fits you is a clinical decision you make with your Arizona-treating provider.

Yes, many patients transfer their care to Pallas. During intake you tell your clinician which medication and dose you take now and how you have tolerated it. Your Arizona-treating provider reviews that history and, if appropriate, continues you at a comparable dose or adjusts your titration plan. Do not stop or change a prescription on your own — let your clinician guide any transition.

Most patients use a once-weekly injection with a very fine needle, but a compounded oral semaglutide tablet is available for people who would rather not inject. Both are prescribed only after a clinician confirms they are appropriate for you, and your provider can help you weigh which form fits your routine and goals.

The most common side effects are gastrointestinal — nausea, constipation, diarrhea, or reflux — and they are usually mildest when the dose is raised slowly, which is why clinicians titrate up gradually. GLP-1s are not right for everyone; they are avoided in people with a personal or family history of medullary thyroid carcinoma or MEN2, and during pregnancy. Your Pallas clinician screens for these before prescribing and stays available to help you manage any side effects.

You complete a detailed online intake in under five minutes, sharing your health history, goals, and current medications. A provider licensed or registered to practice telehealth in Arizona reviews it asynchronously in most cases — no live video required — and may follow up by secure message or request labs if your history calls for it. If a GLP-1 is appropriate, your prescription goes to a licensed pharmacy that ships to any Arizona address, usually within 2–3 business days.

Pallas care is ongoing, not a one-time script. Your plan renews on a regular cadence so your medication arrives before you run out, and your clinician schedules check-ins to monitor your response, adjust your dose, and manage side effects. You can message your care team, change your plan, or cancel anytime from your patient portal — no phone calls or retention hoops.

Compounded semaglutide injection through Pallas is $139 for your first month, then $597 every 12 weeks ($199/mo average). Cancel anytime. That one plan price includes your US-licensed provider, ongoing check-ins, dose adjustments, and unlimited care-team messaging — no separate membership fee. Medication ships free to any Arizona address, only if a clinician prescribes it, and you are refunded in full if a clinician decides treatment isn't right for you.

Compounded tirzepatide injection through Pallas is $179 for your first month, then $897 every 12 weeks ($299/mo average). Cancel anytime. That one plan price includes your US-licensed provider, ongoing check-ins, dose adjustments, and unlimited care-team messaging — no separate membership fee. Medication ships free to any Arizona address, only if a clinician prescribes it, and you are refunded in full if a clinician decides treatment isn't right for you.

Yes. FDA-approved Wegovy^® and Zepbound^® for chronic weight management — plus Ozempic^® and Mounjaro^® for type 2 diabetes — are available to Arizona patients cash-pay from $1069/mo; insurance is not billed. Whether a brand-name or compounded medication is appropriate for you is determined by a clinician licensed in Arizona during intake.

That is a decision you make with your clinician. Semaglutide activates the GLP-1 receptor; tirzepatide activates both the GLP-1 and GIP receptors. In the SURMOUNT-5 head-to-head trial of the FDA-approved products, Zepbound^® (tirzepatide 10 mg or 15 mg weekly) produced greater average weight loss than Wegovy^® (semaglutide 1.7 mg or 2.4 mg weekly) — 20.2% versus 13.7% of body weight over 72 weeks. Wegovy^®'s maximum dose is now 7.2 mg weekly, which was not studied in SURMOUNT-5; in the separate STEP UP trial it reached 18.7% average weight loss over 72 weeks. Clinical trial outcomes for the FDA-approved products have not been established for compounded preparations. Individual results vary. Semaglutide plans cost less and semaglutide has the longer post-market record; a clinician licensed in Arizona weighs your history, goals, and budget to recommend a starting point.